HCC and the Hallmarks of Cancer: steps towards novel therapeutic strategies

THURSDAY 2 FEBRUARY

12.00 – 12.05  Welcome and Introduction
   Helen Reeves, (United Kingdom)
   Tom Luedde, (Germany)

12.05 – 12.30  Opening Lecture: The Challenge - bridging the gap between basic science and clinical practice
   Peter Schirmacher, (Germany)

   Chair: Helen Reeves, (United Kingdom) Jessica Zucman Rossi, (France)
   Identifying candidates – ‘Omics’ & Next-generation Sequencing in HCC.
   Jessica Zucman Rossi, (France)
   Animal models of HCC: Which models mimic best human biology, pathology and genetics?
   Robert Eferl, (Austria)

13.00 – 13.30

13.30 – 14.00  Molecular imaging: principles, progress and application to HCC.
   Twan Lammers, (Netherlands)

14.00 – 14.30  Coffee break

14.30 – 16.30  Session 2: Sustained Proliferative Signalling & Evasion of Growth Suppression
   Chair: Peter Schirmacher, (Germany) Robert Eferl, (Austria)
   MAPKinases in hepatocarcinogenesis
   Erwin Wagner, (Spain)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.00 – 15.30</td>
<td>CAR and Beta catenin</td>
<td>David Moore, United States</td>
</tr>
<tr>
<td>15.30 – 16.00</td>
<td>The MDM2-p53 pathway in cancer</td>
<td>Simone Fulda, Germany</td>
</tr>
<tr>
<td>16.00 – 16.30</td>
<td><strong>ABSTRACT X2</strong></td>
<td></td>
</tr>
<tr>
<td>16.30-17.00</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>17.00 – 19.00</td>
<td><strong>Session 3: The role of the inflammatory microenvironment in HCC</strong></td>
<td><strong>Chair: Robert Thimme, Germany</strong> Frank Tacke, Germany</td>
</tr>
<tr>
<td>17.00 – 17.30</td>
<td>The microenvironment and its contribution to outcome in HCC</td>
<td>Xin Wei Wang, United States</td>
</tr>
<tr>
<td>17.30 – 18.00</td>
<td>Granulocytes in liver Cancer</td>
<td>Derek Mann, United Kingdom</td>
</tr>
<tr>
<td>18.00 – 18.30</td>
<td>Tumour associated antigen responses in HCC</td>
<td>Robert Thimme, Germany</td>
</tr>
<tr>
<td>18.30</td>
<td><strong>Cocktail Reception for all participants and poster session</strong></td>
<td><strong>Authors of abstracts with odd poster numbers to be present at the poster session</strong></td>
</tr>
</tbody>
</table>

**FRIDAY 3 FEBRUARY**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.30 – 10.30</td>
<td><strong>Session 4: Hallmark - Angiogenesis, Invasion and metastases</strong></td>
<td><strong>Chair: Erwin Wagner, Spain</strong> Erica Villa, Italy</td>
</tr>
<tr>
<td>8.30 – 9.00</td>
<td>Prognostic signatures from HCC biopsy</td>
<td>Erica Villa, Italy</td>
</tr>
<tr>
<td>9.00 – 9.30</td>
<td>Endothelial cell metabolism and angiogenesis</td>
<td>Peter Carmeliet, Belgium</td>
</tr>
<tr>
<td>9.30 – 10.00</td>
<td>TGF beta in HCC progression</td>
<td>Isabel Fabregat, Spain</td>
</tr>
<tr>
<td>10.00 – 10.30</td>
<td><strong>TWO ABSTRACTS</strong></td>
<td></td>
</tr>
<tr>
<td>10.30 – 11.00</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>11.00 – 13.00</td>
<td><strong>Session 5: Enabling of replicative Immortality, Genomic Instability and mutation</strong></td>
<td><strong>Chair: Josep Llovet, Spain</strong> Rudolph Lenhard, Germany</td>
</tr>
<tr>
<td>11.00 – 11.30</td>
<td>Telomeres &amp; Telomerase in HCC</td>
<td>Rudolph, Lenhard, Germany</td>
</tr>
<tr>
<td>11.30 – 12.00</td>
<td>Mutations in SPRTN and genomic instability in HCC</td>
<td>Christian Kubisch, Germany</td>
</tr>
<tr>
<td>12.00 – 12.30</td>
<td>Transposable elements and genetic instability</td>
<td>Ruchi Shukla, United Kingdom</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| 12.30–13.00 | Molecular classification and drivers of cholangiocarcinoma  
Josep Llovet, (Spain) |
| 13.00–14:30 | Poster session & lunch break                                       |
| 14.30–16.30 | **Session 6: Deregulation of cellular energetics**  
*Chair:* Peter Jansen, (Netherlands) Matias Heikenwalder, (Germany) |
| 14.30–15.00 | Mechanisms of NASH and NASH-triggered HCC  
*M. Heikenwälder, (Germany)* |
| 15.00–15.30 | Obesity, the gut microbiome and liver cancer  
*Herbet Tilg, (Austria)* |
| 15.30–16.00 | Endoplasmic reticulum stress  
*Eric Chevet, (France)* |
| 16.00–16.30 | Metabolic Receptors in HCC/CCC  
*Peter Jansen, (Netherlands)* |
| 16.30–17.00 | Coffee break                                                        |
| 17.00–18.30 | **Session 7: Cell Death**  
*Chair:* Tom Luedde, (Germany) Derek Mann, (Germany) |
| 17.00–17.30 | Regulated Cell Death pathways in Hepatocarcinogenesis  
*Tom Luedde, (Germany)* |
| 17.30–18.00 | Cell death response pathways in liver cancer  
*Robert Schwabe, (United States)* |
| 18.00–19.00 | Joint translational Key note lecture “The Hallmarks of Cancer in 2016”.  
*Douglas Hanahan, (Switzerland)* |
| 20.00     | Joint Faculty Dinner                                               |
CLINICAL RESEARCH: Liver Cancer Management

SATURDAY 4 FEBRUARY

8.20 – 8.30 Opening address
Franco Trevisani, (Italy) and Alejandro Forner, (Spain)

8.30 – 10.30 Session 1 THE CHANGING EPIDEMIOLOGY
Chair: Franco Trevisani, (Italy) and Jordi Bruix, (Spain)

8.30 – 9.00 Epidemiology of HCC – an introduction.
Massimo Colombo, (Italy)

9.00 – 9.30 How can we assess the risk of HCC development in alcoholic patients?
Pierre Nahon, (France)

9.30 – 10.00 Impact of new antiviral treatments on HCC risk.
George Papatheodoridis, (Greece)

10.00 – 10.30 NAFLD as a risk factor for HCC.
Jean Francois Dufour, (Switzerland)

10.30 – 11.00 Coffee break

11.00 – 13.00 Session 2: DIAGNOSTIC CHALLENGES
Chair: Valerie Vilgrain, (France) and Massimo Colombo, (Italy)

11.00 – 11.30 Surveillance for HCC: whom, how, and how often?
Alejandro Forner, (Spain)

11.30 – 12.00 Diagnosis of HCC by imaging: Can we improve its accuracy?
Carmen Ayuso, (Spain)

12.00 – 12.30 Pathology of HCC: Can we improve the diagnostic accuracy?
Valérie Paradis, (France)

12.30 – 13.00 Refinement of staging and prognosis assessment of HCC:
- Western point of view: Jordi Bruix, (Spain)
- Eastern point of view: Ronnie Poon, (Hong Kong)

13.00 – 13.30 ABSTRACT x 2 OR LONGER LUNCH BREAK

13.30 – 14.30 Lunch BREAK AND POSTER VIEWING

14.30 – 16.30 Session 3: SURGICAL THERAPY
Chair: Vincenzo Mazzaferro, (Italy) and Alejandro Forner, (Spain)

15.00 – 15.30 Extending the boundaries for resection
Daniel Cherqui, (France)

15.30 – 16.00 Resection or RFA as first line treatment for early stage HCC?
Fabio Piscaglia, (Italy)

16.00 – 16.30 Resection vs. Liver Transplantation in HCC.
Liver transplantation for HCC: Can extending criteria be applied in clinical practice?
Vincenzo Mazzaferro, (Italy)

16.30 – 17.00

COFFEE BREAK

17.15 – 19.15

Session 4: LOCOREGIONAL THERAPY
Chairs: Philippe L. Pereira (Germany) and Carmen Ayuso (Spain)

17.15 – 17.45
TACE: Who should be treated, when to stop, how to be done?
Markus Peck-Radosavljevic, (Austria)

17.45 – 18.15
Which is the role of radioembolization in HCC?
Sherrie Bhoori, (Italy)

18.15 – 18.45
Imaging tumor response evaluation in HCC: Room for improvement?
Valérie Vilgrain, (France)

18.45 – 19.15
Can locoregional therapies be combined?
Philippe L. Pereira, (Germany)

SUNDAY 5 FEBRUARY

8.30 – 10.30

Session 5: INTRAHEPATIC CHOLANGIOCARCINOMA: AN EMERGING PROBLEM.
Chairs: Peter Galle, (Germany) and Bruno Sangro, (Spain)

8.30 – 9.00
The changing epidemiology and diagnosis.
Annika Bergquist, (Sweden)

9.00 – 9.30
Surgical therapy in ICC: Resection and liver transplantation.
Ulf P. Neumann, (Germany)

9.30 – 10.00
The role of locoregional therapies in ICC
Stephen Pereira, (United Kingdom)

10.00 – 10.30
Systemic therapy.
Arndt Vogel, (Germany)

10.30 – 11.00
Coffee Break

11.00 – 13.00

Session 6: Systemic treatments and beyond in HCC
Chairs: Tim Meyer, (United Kingdom) and Josep Llovet (Spain)

11.00 – 11.30
Sorafenib in HCC: Is the efficacy predictable?
Maria Reig, (Spain)

11.30 – 12.00
First-line and second-line trials on HCC: Why they have failed?
Peter Galle, (Germany)

12.00 – 12.30
Rationale basis and ongoing trial of immunotherapy.
Bruno Sangro, (Spain)

12.30 – 13.00
Ongoing trial.
Tim Meyer, (United Kingdom)

13.00 End of the conference